1. 1963 First prospective outcome data in 930 patients with more than 5 year median follow up in whom treatment decisions in clinical practice have been made incorporating the 21-Gene Recurrence Score. (September 2015) Authors: Stemmer, S.; Steiner, M.; Rizel, S.; Ben-Baruch, N.; Soussan-Gutman, L.; Rosengarten, O.; Geffen, D.; Nisenbaum, B.; Ryvo, L.; Uziely, B.; Fried, G.; Svedman, C.; Rothney, M.; Klang, S.; Kaufman, B.; Isaacs, K.; Evron, E.; Zidan, J.; Shak, S.; Liebermann, N. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S321 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Clinical utility of the 21-gene Oncotype DX® Recurrence Score® (RS) assay in hormone receptor-positive, HER2-negative breast cancer (BC). (March 2017) Authors: Lau, A.; Miller, D.; Davison, D.; Rothney, M.; Borgen, P. Journal: Breast Issue: Volume 32(2017)Supplement 1 Page Start: S97 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P247 A laboratory comparison of the 21-gene assay and PAM50-ROR. (March 2015) Authors: Alvarado, M.; Prasad, C.; Rothney, M.; Cherbavaz, D.; Sing, A.P.; Baehner, F.; Svedman, C.; Markopoulos, C. Journal: Breast Issue: Volume 24(2015)Supplement 1 Page Start: S110 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P248 The 21-gene breast cancer assay: a roadmap of clinical evidence. (March 2015) Authors: Bayt, T.; Burke, E.; Rothney, M.; Sing, A.P. Journal: Breast Issue: Volume 24(2015)Supplement 1 Page Start: S111 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗